| Literature DB >> 33789666 |
Murtadha D Hssayeni1, Joohi Jimenez-Shahed2, Michelle A Burack3, Behnaz Ghoraani4.
Abstract
BACKGROUND: Unified Parkinson Disease Rating Scale-part III (UPDRS III) is part of the standard clinical examination performed to track the severity of Parkinson's disease (PD) motor complications. Wearable technologies could be used to reduce the need for on-site clinical examinations of people with Parkinson's disease (PwP) and provide a reliable and continuous estimation of the severity of PD at home. The reported estimation can be used to successfully adjust the dose and interval of PD medications.Entities:
Keywords: Deep models; Ensemble; Home monitoring; Inertial sensors; Parkinson’s disease; UPDRS; Wearable sensors
Year: 2021 PMID: 33789666 PMCID: PMC8010504 DOI: 10.1186/s12938-021-00872-w
Source DB: PubMed Journal: Biomed Eng Online ISSN: 1475-925X Impact factor: 2.819
The LOOCV testing correlation () and MAE of the proposed deep models and Gradient Tree Boosting are reported for single models and the ensemble of two or three models of the deep models
| Method | MAE | ||
|---|---|---|---|
| Single | Gradient Tree Boosting | 0.61 | 7.85 |
| Dual-channel LSTM, hand-crafted features | 0.62 | 7.50 | |
| Dual-channel LSTM, hand-crafted features, with transfer learning | 0.67 | ||
| 1D CNN-LSTM for raw signals | 6.93 | ||
| 2D CNN-LSTM for time–frequency data | 0.67 | 7.11 | |
| Ensemble | Dual-channel LSTM, hand-crafted features, with transfer learning 1D CNN-LSTM for raw signals | 0.77 | 6.04 |
Dual-channel LSTM, hand-crafted features, with transfer learning 2D CNN-LSTM for time–frequency data | 0.76 | 5.99 | |
1D CNN-LSTM for raw signals 2D CNN-LSTM for time–frequency data | 0.74 | 6.54 | |
Dual-channel LSTM, hand-crafted features, with transfer learning 1D CNN-LSTM for raw signals 2D CNN-LSTM for time–frequency data | |||
The correlation was significant for all models (i.e., )
Fig. 1The estimated total UPDRS-III scores using the ensemble of the three deep models vs. the gold-standard total UPDRS-III scores
Fig. 2The ensemble model estimations of UPDRS III over time vs. the gold-standard UPDRS III for four PwP. a and b PwP who experienced an improvement in their PD symptoms. c A patient who experienced the return of PD symptoms before taking the next dose of medication. d A similar behavior; however, it also shows a reduction in the symptoms after receiving the second dose. Note that the data used for UPDRS-III estimation were from either before or after the UPDRS-III assessment. As a result, the estimated and gold-standard time points do not coincide. Patient A performed only two UPDRS III assessment. The red arrow indicates medication intake
Fig. 3The total UPDRS-III scores before and 1 h after taking the PD medications from gold-standard measurements (a) and the ensemble model estimations (b). Both the gold-standard and estimated UPDRS-III scores show a significant drop after PD medication intake
Proposed methods in the literature for estimating the severity of PD represented by UPDRS III
| Reference | PwP | Sensors | Method | Unobtrusive | Estimated | Gold-standard | Validation | MAE | |
|---|---|---|---|---|---|---|---|---|---|
| Griffiths et al. [ | 25 | Wrist | Statistical approach | Yes | Bradykinesia score | UPDRS III | Held-out testing set | 0.64 | 18 |
| Parisi et al. [ | 34 | Chest, left and right thighs | Multiple k-Nearest Neighbors models to estimate LA, S2S and G. | No (task-dependent) | Sum of leg agility, sit-to- stand and gait items of UPDRS III | Sum of leg agility, sit-to- stand and gait items of UPDRS III | LOOCV | 0.79 | - |
Rodriguez-Molinero et al. [ | 75 | Waist | Linear regression | No (task-dependent) | Gait item of UPDRS III | UPDRS III | Held-out testing set | -0.56 | - |
| Pulliam et al. [ | 13 | Wrist and ankle | Multiple linear regression models to estimate tremor, bradykinesia and dyskinesia | Yes | Radar chart of PD tremor, bradykinesia and dyskinesia | UPDRS III | - | 0.81 | - |
| Zhan et al. [ | 152 | Smartphone | Rank-based framework for disease severity score [ | No (task-dependent) | Mobile PD score | UPDRS III | Held-out testing set | 0.88 | - |
| Abrami et al. [ | 60 | Both wrists | Clustering and Markov-Chain | Yes | Multi-dimensional scale | Sum of tremor, bradykinesia and gait items of UPDRS III | Held-out testing set | in clinic at home | |
| Butt et al. [ | 64 | Wrist, fingers, and foot | Adaptive neuro- fuzzy inference system | No (task-dependent) | UPDRS III | UPDRS III | Tenfold cross validation | 0.81 | - |
| The developed approach in this study | 24 | Wrist and ankle | Ensemble of dual- Channel LSTM, CNN-LSTM using raw signals and CNN-LSTM using spectrogram | Yes | UPDRS III | UPDRS III | LOOCV | 0.79 | 5.95 |
Fig. 4The structure of the processed data from the 24 subjects. a The rounds’ duration and their UPDRS-III scores are shown for each subject. The color of each bar represents a round of data, and the height of the bar indicates the duration of the round. Each bar’s number shows the UPDRS-III score as determined by the nearest UPDRS assessment to the round. b The rounds’ distribution is displayed based on their UPDRS-III scores
Subject demographics. LEDD stands for Levodopa Equivalent Daily Dose. Values are presented as number or mean ± standard deviation
| Number of subjects | 24 | UPDRS III before medication | 29.7±12.3 |
| Age (y) | 58.9±9.3 | UPDRS III after medication | 17.3±8.4 |
| Sex (M, F) | 14,10 | LEDD (mg) | 1251±468 |
| Disease duration (y) | 9.9±3.7 |
Fig. 5The architectures of the proposed deep models to estimate UPDRS-III score. a Dual-channel LSTM network to estimate UPDRS III from hand-crafted features. b 1D CNN-LSTM network to estimated UPDRS III from raw signals. Each convolutional layer is followed by a ReLU activation layer. Convolutional Block-2 was repeated to increase the depth of the CNN network. c. 2D CNN-LSTM network to estimate UPDRS III from time–frequency representations. The spectrogram of each 1-min window is the input to the CNN network. d The overall architecture of the proposed ensemble model